Mali Zeevi is the founder of BiolineRx. BiolineRx has raised $105M in total funding. Based in Israel.
Mali Zeevi serves as the Chief Financial Officer (CFO) of BioLineRx, an Israeli biopharmaceutical company. BioLineRx is headquartered in Israel and focuses on developing therapies in oncology and rare diseases. The company's American Depositary Shares (ADS) are listed on NASDAQ under the ticker symbol BLRX. BioLineRx's primary product is Motixafortide, a stem cell treatment for multiple myeloma. The company initiated a Phase 1/2a clinical trial of GLIX1 for glioblastoma in March 2026. As of March 31, 2026, BioLineRx reported $17.4 million on its balance sheet.
Full founder directory · Investor directory · Company funding database · Fundraising library